Investment

Sema4, spun out of Icahn School of Medicine, has achieved a valuation of more than $1bn following a $121m series C round.

Funding for HUJ spinouts remained stable during the first six months of 2020 as the Israeli VC sector showed signs of resilience amid Covid-19.

Drug protein discovery company Bright Peak hopes to deliver conjugated cancer immunotherapies based on an ETH Zürich-invented platform.

Co-founded by faculty from Columbia University and University of Melbourne, Praxis Precision Medicines targets CNS disorders.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Enthera Pharmaceuticals was co-founded by faculty from University of Milan and is using stem cells to treat autoimmune disorders.

With hundreds of university venture funds, internal commercialisation vehicles and third-party firms the reality in today’s innovation ecosystem, selecting the nominees and the winner for Investment Unit of the Year is increasingly challenging.

Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.

Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.

Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.